This study is currently not recruiting participants.

Pharmacokinetics of Sildenafil in Premature Infants

Investigating the Dose and Safety of an Investigational Medication in Premature Infants

Not Recruiting
1 years or below
All
Phase N/A

Brief description of study.

The purpose of this research study is to learn more about the dose and safety (side effects) of a medicine called sildenafil when used in premature infants.

Detailed description of study

The purpose of this research study is to learn more about the dose and safety (side effects) of a medicine called sildenafil when used in premature infants.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Premature Infants
  • Age: 1 years or below
  • Gender: All

This study investigates the dose and safety of an investigational medication in premature infants. Premature infants are babies born before 37 weeks of pregnancy. The study aims to understand how the investigational medication affects these infants and to identify any side effects.

Participants will receive either the investigational medication or a placebo. A placebo is an inactive substance that looks like the investigational medication but does not contain any medicine. The study will monitor the infants for any side effects and assess the appropriate dose.

  • Who can participate: The study is open to premature infants, defined as babies born before 37 weeks of gestation. Key eligibility factors include specific health conditions relevant to the study's focus.
  • Study details: Participants will receive either the investigational medication or a placebo. A placebo is an inactive substance that looks like the investigational medication but does not contain any medicine.
Updated on 19 Feb 2024. Study ID: 1212010282

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team